CClinicalTrials.gg
Sign In
Status unknownNCT04600219Updated Nov 3, 2020

The Effect of Tyrosine Kinase Receptor Axl on Dialysis Prognosis in Chronic Hemodialysis Patients

An observational study in Hemodialysis Complication, sponsored by Ai Peng. Status unknown at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2020-11-03.

Sponsored by Ai Peng · Observational

The sponsor has not verified this record recently (last verified Nov 2020), so the status shown — last known as Active, not recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
250
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate whether tyrosine kinase receptor Axl affects the dialysis prognosis in chronic hemodialysis patients

Read the detailed description

It is reported that hemodialysis (HD) patients often develop chronic systemic inflammatoion, and increased inflammatory activity is associated with vascular access failure, cardiovascular disease and death in HD patients. The interaction of Axl and its ligand Gas6 plays an important role in modulating immune response, inhabiting toll-like receptor (TLR) signaling and suppressing inflammatory cytokines production. Thus, we want to investigate the relationship between tyrosine kinase receptor Axl and the dialysis prognosis in HD patients in three-years follow-up.

02

Conditions studied

  • Hemodialysis Complication

Keywords

  • hemodialysis
  • Axl
  • prognosis
03

In context

Lead sponsor

Ai Peng is the lead sponsor of 7 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

End-stage renal disease patients undergoing hemodialysis treatment

Inclusion criteria

  • hemodialysis for more than 6 months

Exclusion criteria

Exclusion Criteria:

  • patients who received warfarin therapy;
  • patients with chronic infectious disease or acute infection;
  • patients with hemodialysis inadequacy;
  • the age of patients is older than 65 years or younger than 18 years.
  • patients who can not sign an informed consent or disagree to follow up
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
250 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. death

    death

    Time frame: 3 years

  2. dialysis complication

    vascular access failure, stroke, acute coronary syndrome, heart failure

    Time frame: 3 years

07

Study locations

1 site
  • Department of Nephrology & Rheumatology, Shanghai Tenth People's Hospital
    Shanghai, Shanghai 200272, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 3, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04600219
Lead sponsor
Ai Peng
Responsible party
Ai Peng (Director of the department of Nephrology,Shanghai 10th people's hospital, Shanghai 10th People's Hospital) — Sponsor-investigator
First posted
Oct 23, 2020
Start date
Jan 1, 2018
Primary completion
Dec 1, 2021 (estimated)
Completion
Dec 1, 2021 (estimated)
Last update
Nov 3, 2020

Study contacts

Ai Peng, MD,PhD
study director · Shanghai 10th People's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

Ai Peng

Start the discussion